EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Repligen's enterprise value is $8,753.9 Mil.
Repligen's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $638.8 Mil. Therefore, Repligen's EV-to-Revenue for today is 13.70.
The historical rank and industry rank for Repligen's EV-to-Revenue or its related term are showing as below:
RGEN'
s EV-to-Revenue Range Over the Past 10 Years
Min: 2.95 Med: 12.59 Max: 35.26
Current: 13.7
During the past 13 years, the highest EV-to-Revenue of Repligen was 35.26. The lowest was 2.95. And the median was 12.59.
RGEN's EV-to-Revenue is ranked worse than 86.06% of 825
companies
in the Medical Devices & Instruments industry
Industry Median: 3
vs RGEN: 13.70
As of today (2024-04-23), Repligen's stock price is $171.28.
Repligen's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $11.27. Therefore, Repligen's PS Ratio for today is 15.20.
Repligen EV-to-Revenue Historical Data
The historical data trend for Repligen's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Repligen's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Repligen EV-to-Revenue Distribution
For the Medical Devices & Instruments industry and Healthcare sector, Repligen's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Repligen's EV-to-Revenue falls into.
Repligen's current Enterprise Value is $8,753.9 Mil.
Repligen's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $638.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Repligen's share price for today is $171.28.
Repligen's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.27.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Repligen EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Repligen's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RGEN has been successfully added to your 